tert-butyl 3,3-dimethylpyrrolidine-1-carboxylate | 851429-33-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl 3,3-dimethylpyrrolidine-1-carboxylate
• 英文别名: 1-t-butoxycarbonyl-3,3-dimethyl-pyrrolidine；tert-butyl 3,3-dimethylpyrrolidinecarboxylate
• CAS: 851429-33-9
• 化学式: C₁₁H₂₁NO₂
• 分子量: 199.293
• InChiKey: OFGFWJUIFJBSFK-UHFFFAOYSA-N

物化性质

• 沸点：
  241.9±9.0 °C(Predicted)
• 密度：
  0.970±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl 3,3-dimethylpyrrolidine-1-carboxylate 在 仲丁基锂 、 三氟乙酸 、 鹰爪豆碱 作用下， 以 甲基叔丁基醚 为溶剂， 反应 23.0h， 生成 (R)-3-(4,4-dimethylpyrrolidin-2-yl)pyridine
  参考文献：
  名称：

  Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates

  摘要：

  A novel series of 3-O-carbamoyl erythromycin A derived analogs, labeled carbamolides, with activity versus resistant bacterial isolates of staphylococci (including macrolide and oxazolidinone resistant strains) and streptococci are reported. An (R)-2-aryl substituent on a pyrrolidine carbamate appeared to be critical for achieving potency against resistant strains. Crystal structures showed a distinct aromatic interaction between the (R)-2-aryl (3-pyridyl for 4d) substituent on the pyrrolidine and G2484 (G2505, Escherichia coli) of the Deinococcus radiodurans 50S ribosome (3.2 angstrom resolution). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.067
• 作为产物：
  描述：

  2,2-二甲基琥珀酸 在 lithium aluminium tetrahydride 、 尿素 作用下， 以 四氢呋喃 为溶剂， 反应 29.0h， 生成 tert-butyl 3,3-dimethylpyrrolidine-1-carboxylate
  参考文献：
  名称：

  Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates

  摘要：

  A novel series of 3-O-carbamoyl erythromycin A derived analogs, labeled carbamolides, with activity versus resistant bacterial isolates of staphylococci (including macrolide and oxazolidinone resistant strains) and streptococci are reported. An (R)-2-aryl substituent on a pyrrolidine carbamate appeared to be critical for achieving potency against resistant strains. Crystal structures showed a distinct aromatic interaction between the (R)-2-aryl (3-pyridyl for 4d) substituent on the pyrrolidine and G2484 (G2505, Escherichia coli) of the Deinococcus radiodurans 50S ribosome (3.2 angstrom resolution). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.067

文献信息

• Site‐Specific Alkene Hydromethylation via Protonolysis of Titanacyclobutanes
  作者：James A. Law、Noah M. Bartfield、James H. Frederich

  DOI：10.1002/anie.202103278

  日期：2021.6.21

  Methyl groups are ubiquitous in biologically active molecules. Thus, new tactics to introduce this alkyl fragment into polyfunctional structures are of significant interest. With this goal in mind, a direct method for the Markovnikov hydromethylation of alkenes is reported. This method exploits the degenerate metathesis reaction between the titanium methylidene unveiled from Cp2Ti(μ-Cl)(μ-CH2)AlMe2

  甲基在生物活性分子中普遍存在。因此，将这种烷基片段引入多官能结构的新策略引起了人们的极大兴趣。考虑到这一目标，报告了一种烯烃马尔可夫尼科夫氢甲基化的直接方法。该方法利用了Cp 2 Ti(μ-Cl)(μ-CH 2 )AlMe 2 (Tebbe试剂)中的钛亚甲基与未活化的烯烃之间的简并复分解反应。所得环丁烷钛的原位质子解作用以化学、区域和位点选择性方式实现氢甲基化。该方法的广泛实用性在一系列含有侧醇、醚、酰胺、氨基甲酸酯和碱性胺的单取代和二取代烯烃中得到了证明。
• EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE
  申请人：Jandeleit Bernd

  公开号：US20090082464A1

  公开（公告）日：2009-03-26

  Masked nitrogen-substituted and oxygen-substituted neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.

  掩蔽的氮取代和氧取代的新戊烷磺酰酯丙戊酸酯前药，包含这种前药的药物组合物，以及使用这种前药和组合物治疗疾病的方法被披露。具体来说，披露了表现出增强口服生物利用度的丙戊酸酯前药和使用丙戊酸酯前药治疗神经退行性疾病、精神疾病、情绪障碍、焦虑障碍、躯体形式障碍、运动障碍、物质滥用障碍、暴饮暴食障碍、皮层扩散性抑郁相关障碍、耳鸣、睡眠障碍、多发性硬化和疼痛的方法。
• Structural studies of {6Li} 2-lithiopyrrolidines using NMR spectroscopy
  作者：Robert E. Gawley、Rosalyn Klein、Neil J. Ashweek、Iain Coldham

  DOI：10.1016/j.tet.2005.01.098

  日期：2005.3

  aggregation and dynamic solvation effects, depending on the nature of the N-substituent and substituents on the pyrrolidine ring. Studies were performed with N-Boc (coordinating carbonyl group), N-methoxyethyl (coordinating methoxy group) and N-alkyl (no coordinating group) heterocycles to represent three different classes of organolithiums: dipole-stabilized, unstabilized and chelated, and unstabilized

  制备了N-取代的2-硫代吡咯烷的选择物，并通过6 Li和13 C NMR光谱研究了它们的结构。根据N-取代基和吡咯烷环上取代基的性质，提供了聚集和动态溶剂化作用的证据。用N- Boc（配位羰基），N-甲氧基乙基（配位甲氧基）和N-烷基（无配位基）杂环进行了研究，以代表三种不同类型的有机锂：偶极稳定，不稳定和螯合以及不稳定。
• DIHYDROPYRROLOPYRIMIDINE DERIVATIVES
  申请人：PFIZER INC.

  公开号：US20150291604A1

  公开（公告）日：2015-10-15

  The present invention relates to compounds of formula (X) or pharmaceutically acceptable salts thereof, wherein R 1 -R 50 , a, b, d, e, f, g, h, i, j, k, l, o, p, q, r, s, t, u, y, and z are defined herein. The novel dihydropyrrolopyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式（X）化合物或其药学上可接受的盐，其中R1-R50，a，b，d，e，f，g，h，i，j，k，l，o，p，q，r，s，t，u，y和z在此定义。这种新型二氢吡咯吡咪啉衍生物在哺乳动物的异常细胞生长，如癌症治疗中有用。其他实施例涉及含有该化合物的制药组合物以及在哺乳动物中治疗异常细胞生长的方法。
• [EN] 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES<br/>[FR] DÉRIVÉS DE 1H-PYRROLO[2,3-B]PYRIDINE COMME INHIBITEURS DE BCL-2 POUR LE TRAITEMENT DE MALADIES NÉOPLASIQUES ET AUTO-IMMUNES
  申请人：NEWAVE PHARMACEUTICAL INC

  公开号：WO2022140224A1

  公开（公告）日：2022-06-30

  The present invention relates to compounds of e.g. formula (I) as BCL-2 inhibitors for the treatment of neoplastic, autoimmune or neurodegenerative diseases. Preferred compounds are e.g. fused 1H-pyrrolo[2,3-b]pyridine derivatives of e.g. formula (II)

  本发明涉及如式（I）的化合物，作为治疗肿瘤、自身免疫或神经退行性疾病的BCL-2抑制剂。优选的化合物是如式（II）的融合1H-吡咯并[2,3-b]吡啶衍生物。